Literature DB >> 8893266

Differential effect of taxol in rat primary and metastatic prostate tumors: site-dependent pharmacodynamics.

W C Yen1, M G Wientjes, J L Au.   

Abstract

PURPOSE: This study compared the sensitivity of rat prostate MAT-LyLu primary and lymph node metastatic tumors to taxol.
METHODS: Tumors were established by subcutaneous implantation of tumor cells in a hind leg (primary site) of male Copenhagen rats. Lymph node metastases were used for serial transplantation. Eleven pairs of primary and metastatic tumors between the sixth and twentieth generations were harvested and maintained as 3-dimensional histocultures. The effects of taxol (24 hr treatment at 1 nM to 10 microM) were measured by the appearance of apoptotic cells, and by the inhibition of DNA precursor (thymidine) incorporation. To determine the basis of differential sensitivity of primary and metastatic tumors to the DNA inhibition, we examined the expression of multidrug resistance pglycoprotein (Pgp) and the accumulation of 3H-taxol after 24 hr exposure and the retention after a 48 hr washout period.
RESULTS: The fraction of apoptotic cells increased linearly with the logarithm of taxol concentration to a maximal value of 25%; the concentration-response curves for primary and metastatic tumors were superimposable. Taxol produced a sigmoidal, concentration-dependent inhibition of thymidine incorporation; the maximal inhibition of approximately 40% was reached at 0.1 and 1 microM for primary and metastatic tumors, respectively. Within the primary or metastatic subgroups, the IC30 (drug concentration that produced a 30% inhibition of DNA synthesis) among consecutive generations varied by < 5 fold, but the primary tumor consistently showed a lower IC30 than the daughter or the parent metastatic tumor (mean, 20-fold; median, 15-fold; range, 6- to 56-fold). The finding that the lower drug sensitivity in metastatic tumors was not exhibited in its daughter primary tumor but was regained in its daughter metastatic tumors suggests that the chemoresistant phenotype is maintained only in lymph nodes and not in the primary site. There were no differences in the Pgp status (neither tumor expressed Pgp), accumulation and retention of taxol in primary and metastatic tumors.
CONCLUSIONS: Taxol induced apoptosis and inhibited DNA synthesis in the rat MAT-LyLu primary and lymph node metastatic tumors. The apoptotic effect was not different among the two tumors, whereas the primary tumor was more sensitive to the inhibition of DNA synthesis. The differential sensitivity of the two tumors to the DNA effect is not associated with a difference in Pgp expression, drug accumulation nor drug retention, and appears to be associated with changes that are linked to lymph node metastasis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8893266     DOI: 10.1023/a:1016053412582

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  33 in total

1.  A phosphoglycoprotein associated with taxol resistance in J774.2 cells.

Authors:  S N Roy; S B Horwitz
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

2.  Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.

Authors:  J E Liebmann; S M Hahn; J A Cook; C Lipschultz; J B Mitchell; D C Kaufman
Journal:  Cancer Res       Date:  1993-05-01       Impact factor: 12.701

3.  Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells.

Authors:  K Bhalla; A M Ibrado; E Tourkina; C Tang; M E Mahoney; Y Huang
Journal:  Leukemia       Date:  1993-04       Impact factor: 11.528

4.  Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines.

Authors:  N M Lopes; E G Adams; T W Pitts; B K Bhuyan
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 5.  Apoptosis. Its significance in cancer and cancer therapy.

Authors:  J F Kerr; C M Winterford; B V Harmon
Journal:  Cancer       Date:  1994-04-15       Impact factor: 6.860

6.  Site-dependent differences in sensitivity of LOX human melanoma tumors in nude rats to dacarbazine and mitozolomide, but not to doxorubicin and cisplatin.

Authors:  I Kjønniksen; K Breistøl; O Fodstad
Journal:  Cancer Res       Date:  1992-03-01       Impact factor: 12.701

7.  Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol.

Authors:  L Milas; N R Hunter; B Kurdoglu; K A Mason; R E Meyn; L C Stephens; L J Peters
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Histocultures of human prostate tissues for pharmacologic evaluation.

Authors:  M G Wientjes; T G Pretlow; R A Badalament; J K Burgers; J L Au
Journal:  J Urol       Date:  1995-04       Impact factor: 7.450

9.  P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine.

Authors:  L A Speicher; L R Barone; A E Chapman; G R Hudes; N Laing; C D Smith; K D Tew
Journal:  J Natl Cancer Inst       Date:  1994-05-04       Impact factor: 13.506

10.  Pharmacodynamics of taxol in human head and neck tumors.

Authors:  Y Gan; M G Wientjes; D E Schuller; J L Au
Journal:  Cancer Res       Date:  1996-05-01       Impact factor: 12.701

View more
  3 in total

Review 1.  Three-dimensional cultures of prostatic cells: tissue models for the development of novel anti-cancer therapies.

Authors:  K C O'Connor
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

2.  Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs.

Authors:  S Song; M G Wientjes; Y Gan; J L Au
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

3.  Effect of sun ginseng potentiation on epirubicin and paclitaxel-induced apoptosis in human cervical cancer cells.

Authors:  Yingjia Lin; Dan Jiang; Yang Li; Xinye Han; Di Yu; Jeong Hill Park; Ying-Hua Jin
Journal:  J Ginseng Res       Date:  2014-08-08       Impact factor: 6.060

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.